Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2025-03-21 Remuneration Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
9.2. Explanatory Note on Remuneration_FR.pdf
Remuneration Information Classification · 100% confidence The document is an explanatory note regarding proposed changes to UCB's remuneration policy for non-executive directors. It details the rationale for these changes, the new peer group selection, and specific compensation tables comparing current vs. proposed figures. This type of document is typically provided to shareholders as part of the materials for an upcoming Annual General Meeting (AGM) to solicit their vote on the new policy. Since it is a detailed document outlining compensation structures and policy changes for shareholder approval, it falls under the Proxy Solicitation & Information Statement category.
2025-03-21 French
8.2. Remuneration_Policy_2025_FR.pdf
Remuneration Information Classification · 100% confidence The document is titled 'Politique de rémunération d'UCB 2025' (UCB Remuneration Policy 2025). It details the compensation philosophy, structure, and policies for the Executive Committee and Non-Executive Directors, including benchmarking against a global peer group and specific changes from the previous year. This type of document is a standard component of proxy materials or governance disclosures provided to shareholders for approval at an Annual General Meeting. Under the provided classification schema, 'DEF 14A' is the designated category for Remuneration Information, which covers executive and director compensation reports.
2025-03-21 French
5.2. UCB_IAR_2024_FR.pdf
Annual Report Classification · 100% confidence The document is titled 'Rapport annuel intégré 2024' (2024 Integrated Annual Report) for UCB Biopharma SRL. It contains a comprehensive overview of the company's performance, strategy, governance, sustainability, and financial sections (as indicated by the table of contents). It is clearly the full annual report rather than an announcement or a summary, as it includes detailed management reports, financial disclosures, and audit references. FY 2024
2025-03-21 French
4.3. UCB_SA_Statutory Auditor Report 2024 NL.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Verslag van de commissaris' (Auditor's Report) for UCB NV for the fiscal year ending December 31, 2024. It contains the auditor's opinion on the financial statements, key audit matters, and responsibilities of the board and the auditor. This is a standalone audit report document, not the full Annual Report itself, and it does not fit the criteria for an announcement (RPA) or other categories. FY 2024
2025-03-21 Dutch
5.3. UCB_ IAR _2024_NL.pdf
Annual Report Classification · 100% confidence The document is titled 'Geïntegreerd jaarverslag 2024' (Integrated Annual Report 2024) for UCB Biopharma SRL. It contains a comprehensive overview of the company's performance, strategic report, sustainability statement, governance information, and references to financial statements (Jaarrekening). It is clearly the full annual report for the fiscal year 2024, not an announcement or a summary. FY 2024
2025-03-21 Dutch
6.3. Statutory Accounts NBB_UCB SA_31.12.2024 _NL Final.pdf
Annual Report Classification · 100% confidence The document is a formal Belgian 'Jaarrekening' (Annual Accounts) for UCB SA, which includes balance sheets, lists of directors, and financial statements for the fiscal year 2024. This is a comprehensive statutory financial report required by law, fitting the definition of an Annual Report (10-K equivalent in this context). FY 2024
2025-03-21 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.